ReviewFrontiers in molecular biosciences2025
SOX9: a novel janus-faced regulator in immunity and its promise as a therapeutic target.
Review in Frontiers in molecular biosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The Sex-determining Region Y-related High-Mobility Group Box 9 (SOX9), a key transcription factor in the SOX family, plays essential roles in various biological processes, particularly in the development of the tumor microenvironment and the repair of inflamed tissues. Findings: This review elucidates the structure of SOX9 and its relationship with immune components from an immunological perspective, it analyzes the mechanisms by which SOX9 operates in tumor immune escape, inflammatory diseases and tissue repair (such as in osteoarthritis, OA), Furthermore, it introduces a novel immunological perspective by investigating the therapeutic potential and application strategies of SOX9 for treating tumors and inflammatory diseases. and reviews the latest advances in SOX9-related treatments. Conclusion: SOX9 plays a complex and dual role in immunology, acting as a "double-edged sword". On one hand, it promotes immune escape by impairing immune cell function, making it a potential therapeutic target in cancer. On the other hand, increased levels of SOX9 help maintain macrophage function, contributing to cartilage formation, tissue regeneration, and repair. Given its significant role in immunobiology, SOX9 represents a promising therapeutic candidate for cancer and immune-related diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.